(**Mass Campaign**）

:

:

amoradi135@yahoo.com   :

:

:

/ / :   **/ /** :

:

:

.

.   .

.   :

.   (   )

.   .

Reliability.   OR
Constract Validity.

.   Principal Components Analysis

% / % / % /   .   :

.

.   .

.   :

.   "

.

KAP Mass Campaign   :

%

(%)   %   .

.

(   )   .( )
(   )
.( )   WHO   (EPI)
WHO .   UNICEF

.   /

.

%
.( )   %

Mass)
.   (Campaign

.( )

( )   –
.   .
.
.

P= /
.   /
....

.   (proportional   allocation)

.

.   .

.

.

.   .

.   (% /)   (% /)   .
   (%   CI= % /   % /   % /)
% /)   (%   CI= % /   % /   % /)
                              (%   CI= % /   % /

                    .   .   OR

                                           t
                        P < /   .

           P = /   .
                  .(   )   Reliability
                                                  Internal Consistency

                                               .

              .   .   .   .   /
                                           Validity   .   Reliable
                         .   Content Validity

                                                 .
                                   (Constract Validity)
              .
                      (Factor Analysis)
                                                 .
              .   %

        .   .
                              (Principle Components
                                  .( )   Analysis)

        Forward Stepwise (Conditional)

MR

/ .

% / .

% / .

/ .

/ .

% /

. .

%

/ / % / .

% /

MR

% / .

.( )

% .

MMR

Ronne % .

% : % / .

"

% . % .

(MMR)

% / .

.

.( ) % / .

Isomura .

% / % /

.

.

MR

. .

.

.

.

.

.

.

Internal

Consistency .( )

Principal Component Analysis

Valied

. .

Odds Ratio

.

. .

"

.

.

.

:

	/		/	
	/		/	
	/		/	

$\chi^2_{=31.48}$
P-Value < 0.001
OR= 3.31
%95 CI OR= (2.16 ,5.07)

:

	/		/	
	/		/	
	/		/	

$\chi^2_{=8.92}$ P-Value = 0.003
OR= 3.58   %95 CI OR= (1.47 , 8.68)

:

$\chi^2 = 6.04$ /
P-Value /
= 0.19

$\chi^2 = 3.39$ /
P-Value /
= 0.06

/

t = 1.20 /
P value = /
0.23

/

t = 2.08 /
P value = /
0.03

$\chi^2 = 2.50$ /
P-Value
= 0.47

/
t = 1.51 /
P-Value
= 0.13 /

/ $\chi^2 = 16.98$ /

$\chi^2 = 2.45$ /
P-Value P-Value /
= 0.29 = 0.002

/ /

$\chi^2 = 5.23$ /
P-Value /
= 0.26

/ $\chi^2 = 0.05$ /
P-Value /
= 0.81

/ $\chi^2 = 9.81$ /
P-Value /
/ = 0.08

$\chi^2 = 10.84$ /
P-Value /
= 0.02 /
/
/
/

:

$\chi^2 = 2.86$	/	$\chi^2 = 2.44$	/
P-Value = 0.58	/	P-Value = 0.11	/
	/	t = 1.83	/
	/	P-Value = 0.06	/
	/	t = 1.64	/
$\chi^2 = 2.76$	/	P-Value = 0.10	/
P-Value = 0.43	/	t = 2.12	/
	/	P-Value = 0.03	/
	/	$\chi^2 = 11.60$	/
$\chi^2 = .27$	/	P-Value = 0.02	/
P-Value = 0.87	/		/
	/		/
$\chi^2 = 2.80$	/		/.
P-Value = 0.59			
	/	$\chi^2 = 3.92$	/
	/	P-Value = 0.04	/
	/	$\chi^2 = 9.30$	/
	/	P-Value = 0.09	/
$\chi^2 = 7.18$	/		/
P-Value = 0.12	/		/
	/		/
	/		/
	/		

:

$\chi^2 = 0.57$	/	$\chi^2 = .75$	/
P-Value = 0.96	/	P-Value = 0.38	/
	/	t = 0.40	/
	/	P-Value = 0.68	/
	/	t = -0.85	/
$\chi^2 = 2.27$	/	P-Value = 0.39	/
P-Value = 0.51	/	t = 0.32	/
	/	P-Value = 0.74	/
	/	$\chi^2 = 18.47$	
$\chi^2 = 1.40$	/	P-Value = 0.001	/
P-Value = 0.49	/		/
	/		/
$\chi^2 = 1.94$	/		/
P-Value = 0.74			
	/	$\chi^2 = 5.48$	/
	/	P-Value = 0.01	/
	/	$\chi^2 = 10.92$	/
	/	P-Value = 0.05	/
$\chi^2 = 5.26$	/		/
P-Value = 0.26	/		
	/		/
	/		/
	/		

References

Supplement 1: 63-68.

7- 6-Bino S, Kakarriqi E, Xibiniku M, Iononedeleu N, Emiroglu N and Uzicamin A, Mass Immunization Campaign in Albania, November 2000.journal of Infectious Diseases, 2003; 187 Supplement 1:223-229.

8- Quedros C, Izurieta H, Carrasco P and Tambini G, Monitoring Measles Eradication in the Region of the Americas: Critical Activities and Tools, The Journal of Infectious Diseases, 2003; 187,Supplement1: 102-110.

9- Pistol A, Hennesey K, Pitigoi D, Ionedelcu N, Walls L, Bellini W, and Strebel P, Progress toward Measles Elimination in Romania after a Mass Vaccination Campaign and Implementation of Enhanced Measles Surveillance, Journal of Infectious Diseases, 2003; 187 Supplement 1:217-222.

10- Alvin C, Methods of Multivariate Analysis Second Edition Brigham Young University, 2002.

11- Ronne T, Kaaber K, Petersen I, Knowledge of, attitudes toward and participation in the new vaccinations against measles, mumps and rubella during the first 2 years, Ugeskr Laeger, 1989;151(38):2418-22.

12- Isomura S, Ahmed A, Dure-Samin A, Mubina A and Takasu T, Epidemiological studies on measles in Karachi, Pakistan--mothers' knowledge, attitude and beliefs about measles and measles vaccine, Acta Paediatr Jpn, 1992;34(3): 290-294.

Lot Quality Assurance

Sampling

.

3- Gaafar E. Moshni G and Lievano F, The Challenge of Achieving Measles Elimination in the Eastern Mediterranean Region by 2010. Journal of Infectious Diseases, 2003; 187 Supplement 1:246-251.

4- Forrest J, Burgess M, Heath T and Mcintyre P, Measles control in Australia . Communicable Diseases Intelligence, 1998; 22(3) :33-36.

5- Kambir C, Kader Konde M, Yameogo A, and Tiendrebeogo S, Measles Incidence Befor and After Mass Vaccination Campaigns in Burkina Faso. journal of Infectious Diseases, 2003; 187 Supplement 1:86-90.

6- Nanyuja M, Lewis R, Makumbi I, Seruyange R, Kabwongera E, Mugyenyi P and Talisuma A, Impact of Mass Measles Campaigns among Children Less Than 5 Years Old in Uganda . The journal of Infectious Diseases, 2003;187